

March 28, 2024

<b>To</b>  Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	<b>To</b>  The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir / Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref : Our disclosure letters dated September 1, 2022 and October 11, 2023**

Further to our disclosure letters dated September 1, 2022 and October 11, 2023 informing about (i) expansion of the biologics manufacturing facilities and exploring the possibilities to enter into contract manufacturing operations (“**CMO**”) for biologicals, and (ii) execution of a limited Letter of Intent (“**LOI**”) between CuraTeQ Biologics Private Limited (“**CuraTeQ**”), a wholly owned subsidiary of the Company along with its subsidiary(ies), and Merck Sharp & Dohme Singapore Trading Pte. Ltd. and its affiliates (“**MSD**”), whereby the parties intended to conclude the negotiations by March 31, 2024.

In this regard, we further inform you that said negotiations are yet to be concluded and the parties to the LOI have agreed to extend the timelines with the intention to conclude the said negotiations by May 31, 2024.

The Company will provide further updates as the transaction progresses.

Please take the above information on record.

Yours faithfully,

**For AUROBINDO PHARMA LIMITED**

**B. Adi Reddy**  
**Company Secretary**

**AUROBINDO PHARMA LIMITED**

[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833

Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)